CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
about
Contribution of personalized Cyclin D1 genotype to triple negative breast cancer riskEffect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis.Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue.Automated Quantitative Analysis of p53, Cyclin D1, Ki67 and pERK Expression in Breast Carcinoma Does Not Differ from Expert Pathologist Scoring and Correlates with Clinico-Pathological Characteristics.Neoadjuvant chemotherapy is associated with improved survival compared with adjuvant chemotherapy in patients with triple-negative breast cancer only after complete pathologic response.Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers.Integrated analysis of differentially expressed genes and pathways in triple‑negative breast cancer.The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Triple negative breast cancer: the kiss of death.Piperlongumine, an alkaloid causes inhibition of PI3 K/Akt/mTOR signaling axis to induce caspase-dependent apoptosis in human triple-negative breast cancer cells.Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping.Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients.Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis.
P2860
Q34691871-17828850-6602-4D36-A47C-3A9F4A777E85Q35759050-01597BB9-8037-4300-87FF-9F9587BB6D5EQ36639221-6E31DC2E-FBF1-4F48-8CE7-2235A4503BEEQ37017051-802F1024-A041-4612-A6C9-8A4A2D7FA0ECQ37482192-83149DBD-B2F6-409A-A44F-B099B43700B0Q37704344-3F596534-0043-44D1-AA42-E4A74A08D0EBQ37722121-B70E0473-C744-40DD-9584-5BB18762A0C5Q38771946-3BB64BDE-7372-41EB-B610-E6C7D9EC23FFQ38818744-55AC8A52-4327-45D4-AB2E-31ECF97EADA5Q39004520-1AFDFC10-9BB6-4A33-96D5-459A4E996E2DQ47100468-FA28A2F2-2CBC-4190-AE43-9AC00F3E31F0Q48364519-83B16D90-7F7B-4E25-991B-C56356CFD43EQ49486164-D1B0F4A0-1088-4DF6-8FB8-334DBDC10407
P2860
CK5/6, EGFR, Ki-67, cyclin D1, and nm23-H1 protein expressions as predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
CK5/6, EGFR, Ki-67, cyclin D1, ...... gative breast cancer patients.
@en
CK5/6, EGFR, Ki-67, cyclin D1, ...... gative breast cancer patients.
@nl
type
label
CK5/6, EGFR, Ki-67, cyclin D1, ...... gative breast cancer patients.
@en
CK5/6, EGFR, Ki-67, cyclin D1, ...... gative breast cancer patients.
@nl
prefLabel
CK5/6, EGFR, Ki-67, cyclin D1, ...... gative breast cancer patients.
@en
CK5/6, EGFR, Ki-67, cyclin D1, ...... gative breast cancer patients.
@nl
P2093
P2860
P1433
P1476
CK5/6, EGFR, Ki-67, cyclin D1, ...... gative breast cancer patients.
@en
P2093
Jian-dong Wang
Yan-jun Zhang
Yi-qiong Zheng
P2860
P2888
P304
P356
10.1007/S12032-010-9742-6
P478
28 Suppl 1
P577
2010-11-16T00:00:00Z
P6179
1021997708